Voluntary nationwide recall: Clonazepam (Endo – November)

Dec. 2024Pharmacy Updates

Endo USA Inc. has recalled certain lots of Clonazepam Orally Disintegrating Tablets, USP (C-IV). This is an expansion of a previous recall by Endo. Clonazepam is used to treat panic disorder and certain seizures.

This product is being recalled because the cartons of some packs show the incorrect product strength. The blister strips inside the product pack show the correct strength.

Using this drug at a higher dose than prescribed may cause sleepiness, dizziness, loss of muscle control, and confusion.

To see if your medication was recalled, please contact your doctor or the pharmacy where you received it or visit the FDA website below. If you have an affected lot of Clonazepam, you should stop using the medicine and return it to the place where you got it or throw it away.

As of Nov. 18, there had been no reports of adverse events related to this recall.

To learn more about this recall:

  • Call Inmar Inc. at 1-855-589-1869. Help is available Monday through Friday from 9 a.m. to 5 p.m. EST.
  • Visit the FDA website.

Recent Announcements

Voluntary nationwide recall: True Metrix (Trividia – May)

Trividia Health is recalling all True Metrix Blood Glucose Systems for an issue with the software design of the E-5 Error Code and instructions for the user in the “Messages” section of the Owner’s Booklet/System instructions for use and online labeling and help guides.
May 2026Pharmacy Updates

Community Care Behavioral Health is excited to announce this free upcoming web-based training opportunity:

A growing body of U.S. and international research demonstrates that the rapid legalization and commercialization of gambling—including online casinos and mobile sports betting platforms—are associated with significant and escalating gambling related harm. Although Pennsylvania specific prevalence data remain limited, available evidence is increasingly concerning, with gambling disorder linked to alarmingly high rates of suicide, psychiatric comorbidity, and social and financial harm. Drawing on lessons from the tobacco and opioid crises, this presentation will examine how delayed recognition and regulation can amplify population level harm, underscoring the need for earlier screening, prevention, and policy engagement. Participants will gain practical guidance on identifying patients at elevated risk, implementing evidence informed screening and diagnostic strategies, and applying current treatment approaches across the lifespan.
May 2026Education/Webinars

Bridging Smiles and Systems: Collaborative Care for Children with Chronic Conditions

Please join us for a live, CME-accredited and CEU-accredited webinar on May 13 from noon to 1p.m., that will explore the critical connection between oral health and pediatric chronic conditions such as diabetes, asthma, congenital heart disease, and ADHD.
Apr. 2026Education/Webinars